Prevention & Treatment of Vascular Cognitive Impairment
Vascular cognitive impairment (VCI) is a major contributor to age-related cognitive decline, both independently and as a component of mixed-etiology dementia syndromes. Despite its prevalence, there is no FDA-approved therapy specifically for VCI. Management therefore centers on aggressive cerebrovascular risk factor modification, secondary stroke prevention, and symptomatic pharmacotherapy. Even modest improvements in individual risk factor control may significantly reduce VCI burden at the population level. Preventive strategies initiated in midlife are critical, as small vessel ischemic disease begins decades before clinical cognitive decline, and the overarching goal extends beyond preventing direct vascular brain injury to preserving cognitive reserve so that function is maintained in the presence of copathologies common in older age.
Bottom Line
- No disease-specific therapy exists: There is no FDA-approved treatment for VCI; management relies on vascular risk factor modification and secondary stroke prevention
- Blood pressure control is paramount: SPRINT MIND demonstrated that intensive SBP control (<120 mmHg) reduces the combined rate of MCI and dementia; intensive treatment increases rather than decreases cerebral blood flow
- Multidomain intervention works: The FINGER trial showed that combined diet, exercise, cognitive training, and vascular risk management reduces cognitive decline in at-risk older adults
- Cholinesterase inhibitors have limited evidence: Donepezil has shown modest cognitive benefit in vascular dementia; memantine improves cognition in VCI due to small vessel disease, but effects are small
- Midlife is the window: Vascular risk factors in midlife — hypertension, dyslipidemia, diabetes, smoking, obesity — are associated with later amyloid pathology and cortical neurodegeneration; early intervention is essential
- Post-stroke cognitive impairment is common: Up to 60% of stroke survivors develop cognitive impairment within the first year; individualized secondary prevention is critical to preserve remaining cognitive function
- Life’s Essential 8: The AHA framework targeting diet, physical activity, nicotine avoidance, sleep, BMI, blood lipids, blood glucose, and blood pressure provides an evidence-based prevention roadmap
Blood Pressure Management
Hypertension is the single most important modifiable risk factor for VCI. It drives white matter hyperintensity progression, lacunar infarction, cerebral microbleeds, and accelerated brain atrophy. Three landmark randomized controlled trials have established the benefit of blood pressure lowering for cognitive outcomes in older adults.
| Trial | Population | Intervention | Key Cognitive Findings |
|---|---|---|---|
| Syst-Eur | Older adults with isolated systolic hypertension | Nitrendipine-based antihypertensive regimen vs. placebo | 50% reduction in dementia incidence over 2 years |
| PROGRESS | Patients with prior stroke or TIA | Perindopril ± indapamide vs. placebo | Reduced risk of cognitive decline in patients with recurrent stroke; greatest benefit with dual therapy |
| SPRINT MIND | Adults ≥50 years with SBP 130–180 mmHg | Intensive (SBP <120 mmHg) vs. standard (SBP <140 mmHg) | Reduced combined risk of MCI and dementia; reduced MCI alone; increased cerebral blood flow on ASL MRI |
SPRINT MIND — Clinical Implications
- The parent SPRINT trial was terminated early due to a 25% reduction in major cardiovascular events and significant all-cause mortality reduction with intensive BP control
- SPRINT MIND subsequently demonstrated a 19% reduction in combined MCI and probable dementia with intensive treatment (HR 0.85; 95% CI 0.74–0.97)
- Intensive treatment was associated with increased cerebral blood flow on arterial spin labeling MRI — countering the concern that aggressive BP lowering might cause cerebral hypoperfusion
- The study was limited by early termination (median follow-up 3.34 years) — a longer trial may have shown significant dementia reduction alone
- Target SBP <120 mmHg is reasonable for many older adults, though individualization is needed for patients with orthostatic hypotension, carotid stenosis, or advanced frailty
Blood Pressure Targets in Specific Populations
In patients with cerebral amyloid angiopathy (CAA), strict blood pressure management is doubly important: hypertension increases the risk of lobar hemorrhage, and CAA-related vascular dysfunction impairs cerebral autoregulation. Conversely, in patients with high-grade carotid stenosis, excessively aggressive BP lowering may worsen hemispheric hypoperfusion, and targets should be individualized. Data from the CREST-2 trial showed that 70% or greater asymptomatic carotid stenosis is associated with cognitive impairment, and that carotid endarterectomy may improve cerebral blood flow and cognition.
Multidomain Lifestyle Interventions
The recognition that VCI results from the cumulative impact of multiple risk factors has spurred interest in multidomain interventions that target several risk factors simultaneously. Three major RCTs have tested this approach, with divergent results.
FINGER Trial — The Landmark Positive Result
- Design: 2-year RCT of 1,260 at-risk adults aged 60–77 years from Finland
- Intervention: Combined nutritional guidance (modified Nordic diet), exercise program (aerobic + resistance + balance), cognitive training, and intensive vascular risk factor management
- Primary outcome: Significant 25% relative improvement in overall cognitive performance (NTB composite z-score) in the intervention group vs. control
- Domain-specific benefits: Executive function (83% improvement) and processing speed (150% improvement) showed the greatest gains
- FINGER has spawned the Worldwide FINGERS network — over 40 countries are now adapting the intervention for culturally diverse populations
MAPT (Multidomain Alzheimer Prevention Trial) and preDIVA (Prevention of Dementia by Intensive Vascular Care) failed to show significant cognitive benefit on their primary outcomes. Differences in participant age at enrollment, intervention intensity, adherence rates, and follow-up duration may explain these discrepancies. Notably, preDIVA did show benefit in a subgroup of participants with untreated hypertension at baseline, reinforcing the primacy of blood pressure control.
Exercise & Physical Activity
Physical activity is one of the most consistently supported modifiable risk factors for dementia prevention. Exercise reduces cardiovascular risk factors, promotes cerebral perfusion, enhances neurogenesis and synaptic plasticity, and reduces neuroinflammation. The AHA recommends ≥150 minutes per week of moderate-or-greater-intensity physical activity as part of Life’s Essential 8.
Post-Stroke Cognitive Rehabilitation
Poststroke cognitive impairment occurs in up to 60% of survivors within the first year. Physical exercise combined with cognitive rehabilitation is a mainstay of post-stroke recovery. Some degree of cognitive recovery is expected within the first 6 months after stroke, and structured rehabilitation programs targeting both motor and cognitive domains can optimize this recovery window. Aerobic exercise post-stroke has been shown to improve executive function and processing speed — the cognitive domains most affected by cerebrovascular disease.
Pharmacologic Treatment of VCI
No pharmacologic agent has FDA approval specifically for VCI or vascular dementia. However, limited evidence supports the use of cholinesterase inhibitors and memantine, particularly in the context of mixed AD/vascular dementia where both pathologies are commonly present.
| Agent | Mechanism | Evidence in VCI | Clinical Considerations |
|---|---|---|---|
| Donepezil | Cholinesterase inhibitor | 24-week RCT showed significant improvement in cognitive function (ADAS-cog) and global function (CIBIC-Plus) in vascular dementia | Most evidence in mixed AD/vascular dementia; GI side effects common; may worsen bradycardia |
| Memantine | NMDA receptor antagonist | RCT demonstrated significant cognitive benefit in VCI due to small vessel ischemic disease (ADAS-cog improvement) | Generally well tolerated; may be combined with cholinesterase inhibitors; consider in subcortical vascular dementia |
| Galantamine | Cholinesterase inhibitor + nicotinic receptor modulator | Studied in mixed AD/vascular dementia; modest cognitive and functional benefit in some trials | Dual mechanism may confer additional benefit; limited pure VCI data |
| Rivastigmine | Cholinesterase inhibitor (AChE + BuChE) | Limited data in pure VCI; may be considered in mixed dementia | Transdermal patch improves tolerability; no robust VCI-specific evidence |
Limitations of Pharmacotherapy in VCI
- Effect sizes for cholinesterase inhibitors and memantine in VCI are modest and clinically uncertain — benefits are smaller than in AD
- Vascular dementia is heterogeneous (multi-infarct, subcortical, strategic infarct, mixed), and treatment response varies by subtype
- White matter hyperintensities disrupt cholinergic pathways, providing a rationale for cholinesterase inhibitor use, but the degree of cholinergic deficit varies widely
- Mixed AD/vascular dementia is extremely common; in practice, these patients are often treated with standard AD medications, though the vascular component does not have its own evidence-based pharmacotherapy
- No pharmacologic agent has been shown to slow or reverse the progression of underlying cerebrovascular disease
Management of CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary form of VCI, caused by NOTCH3 gene variants. It presents with migraine, subcortical strokes, and young-onset vascular cognitive impairment. No randomized controlled trials have been conducted specifically in CADASIL. Current management recommendations include:
- Migraine prophylaxis: Valproic acid is preferred; beta-blockers should be avoided due to a higher incidence of reported side effects in CADASIL
- Stroke prevention: Low-dose aspirin in those with a history of ischemic stroke
- Cognitive symptoms: Trials of memantine, donepezil, or both may be considered
- Cardiovascular risk management: Blood pressure and lipid optimization remain important even in a genetic arteriopathy
- Genetic counseling: Should be offered to at-risk family members; NOTCH3 mutation location partially explains disease severity
Smoking Cessation & Other Risk Factor Modification
Beyond blood pressure, the AHA’s Life’s Essential 8 framework identifies seven additional metrics for optimal cardiovascular health, all of which are relevant to VCI prevention. Smoking is a potent risk factor for both stroke and progressive white matter hyperintensity accumulation, and cessation at any age provides benefit.
| Risk Factor | Mechanism of VCI Contribution | Intervention Target |
|---|---|---|
| Hypertension | White matter injury, lacunar infarcts, microbleeds, impaired autoregulation | SBP <120 mmHg (SPRINT MIND); individualize in frail/elderly |
| Diabetes mellitus | Accelerated small vessel disease, white matter hyperintensity progression, neurodegeneration | HbA1c <5.7% (ideal); avoid hypoglycemia in elderly |
| Dyslipidemia | Midlife dyslipidemia associated with later amyloid deposition on PET; atherosclerosis accelerates cerebrovascular disease | Non-HDL cholesterol <130 mg/dL; statin therapy per cardiovascular risk |
| Atrial fibrillation | Cerebral microinfarcts, hypoperfusion, inflammation; strongest AF–dementia association in younger patients with longer AF duration | Anticoagulation per CHA2DS2-VASc score; rhythm/rate control |
| Smoking | Accelerates white matter hyperintensity progression, promotes atherosclerosis, increases stroke risk | Complete cessation; pharmacotherapy (varenicline, NRT) as needed |
| Obesity | Associated with cortical thinning in AD-vulnerable regions independent of amyloid; increases cardiometabolic risk | BMI <25 kg/m²; combined diet and exercise approach |
| Physical inactivity | Reduced cerebral perfusion, impaired neuroplasticity, worsened cardiometabolic profile | ≥150 min/week moderate-or-greater intensity activity |
| Poor sleep | Impaired glymphatic clearance; obstructive sleep apnea contributes to intermittent hypoxemia and white matter injury | 7–9 hours nightly; screen and treat obstructive sleep apnea |
Secondary Stroke Prevention
For patients who have already suffered a clinical stroke or TIA, individualized secondary prevention is critical to preserve cognitive function and prevent new vascular brain injury. The 2021 AHA/ASA guidelines for secondary stroke prevention provide a comprehensive framework. Key considerations for cognitive preservation include:
- Antiplatelet therapy: Aspirin, clopidogrel, or combination aspirin/dipyridamole based on stroke subtype; dual antiplatelet therapy (DAPT) with aspirin + clopidogrel for 21 days after minor stroke or high-risk TIA (CHANCE/POINT trials)
- Anticoagulation for atrial fibrillation: Direct oral anticoagulants (DOACs) preferred over warfarin; apixaban, rivaroxaban, dabigatran, or edoxaban per guidelines
- Statin therapy: High-intensity statins for atherosclerotic stroke; evidence of anti-inflammatory and endothelial-protective effects beyond lipid lowering
- Carotid revascularization: Consider carotid endarterectomy or stenting for high-grade symptomatic stenosis; CREST-2 data suggest cognitive benefit may accompany improved cerebral blood flow
- Blood pressure control: Initiate or optimize antihypertensive therapy after the acute stroke period
Antiplatelet and Anticoagulant Cautions in CAA
- Patients with cerebral amyloid angiopathy are at heightened risk for lobar hemorrhage; antiplatelet and anticoagulant therapies may increase this risk
- If T2* or SWI MRI shows multiple lobar microbleeds or cortical superficial siderosis consistent with CAA, the risk-benefit ratio of antithrombotic therapy must be carefully weighed
- Transient focal neurologic episodes (TFNEs) in CAA may mimic TIA or stroke — standard stroke prevention interventions (thrombolytics, antiplatelets) can increase hemorrhage risk in these patients
- Obtain T2* or SWI MRI sequences in the workup of any patient with transient neurologic symptoms, particularly those ≥55 years, to exclude CAA before initiating antithrombotic therapy
Cardiac Disease & Cognitive Preservation
Cardiovascular dysfunction — including atrial fibrillation, congestive heart failure, and coronary artery disease — independently increases VCI risk through mechanisms including microinfarcts, global hypoperfusion, systemic inflammation, and microhemorrhages. Congestive heart failure confers a 60% increase in dementia risk. Acute myocardial infarction is associated not with immediate cognitive decline but with an accelerated trajectory of progressive cognitive decline over subsequent years. In the Rotterdam Study, decreased cerebral perfusion predicted both faster cognitive decline and increased dementia risk, most prominently in those with greater white matter hyperintensity burden.
Atrial Fibrillation & Dementia Prevention
- AF is independently associated with cognitive decline and increased dementia risk, even in the absence of clinical stroke
- The AF–dementia association is strongest in younger patients and those with longer AF duration
- Proposed mechanisms: cerebral microinfarcts from subclinical embolization, chronic cerebral hypoperfusion, and systemic inflammation
- Anticoagulation reduces stroke risk but whether it directly reduces dementia risk independent of stroke prevention remains under investigation
- Optimal rate and rhythm control may help maintain cerebral perfusion — an active area of research
Vascular Risk Factors & Alzheimer Disease Pathology
Accumulating evidence demonstrates that cerebrovascular risk factors are linked not only to VCI but also to AD pathology. Cerebrovascular disease lowers the threshold for the clinical expression of dementia when combined with neurodegenerative pathologies. Whether these effects are additive but independent of, or synergistic with, AD pathology remains under active investigation.
- Midlife elevation of triglycerides is associated with decreased CSF A-beta and increased phosphorylated tau later in life
- Greater midlife vascular risk is associated with elevated amyloid on PET imaging more than 20 years later
- Midlife dyslipidemia specifically is associated with greater later-life amyloid deposition on Pittsburgh Compound B-PET
- Vascular risk factors including obesity, smoking, diabetes, and hypertension are associated with decreased cortical thickness in AD-vulnerable regions, independent of amyloid — suggesting AD-independent neurodegeneration
- Circle of Willis atherosclerosis score correlates with higher neuritic plaque density, neurofibrillary tangle density, and CAA severity at autopsy
- These findings reinforce that midlife vascular risk factor control is a potentially modifiable pathway to reducing both vascular and neurodegenerative dementia risk
The Perivascular Space & Emerging Targets
The perivascular space has emerged as a critical mediator linking cerebrovascular dysfunction to neurodegenerative pathology. It functions as a component of the brain waste clearance system (the glymphatic pathway), facilitating the removal of toxic solutes including soluble A-beta and tau. Impaired perivascular drainage — from hypertension, CAA, or age-related vascular stiffening — may accelerate both amyloid deposition and neurodegeneration.
- MR-visible perivascular spaces in the centrum semiovale are associated with increased dementia risk and are linked to AD and CAA; basal ganglia perivascular spaces are more associated with hypertensive small vessel disease
- Perivascular clearance may be facilitated by cardiac-related vascular pulsations and vascular smooth muscle cell vasomotor activity, both of which decline with age and vascular disease
- Sleep may enhance glymphatic clearance, providing a mechanistic rationale for the inclusion of sleep health in Life’s Essential 8
- Interventions that improve vascular compliance and reduce arterial stiffness (exercise, BP control) may indirectly enhance perivascular waste clearance
Vascular Contraindications to Anti-Amyloid Therapy
The FDA approval of anti-amyloid monoclonal antibodies (e.g., lecanemab) for early AD raises important considerations for patients with concurrent cerebrovascular disease. Amyloid-related imaging abnormalities (ARIA) — both edema (ARIA-E) and hemorrhage (ARIA-H) — share features with CAA-related inflammation, suggesting a common mechanism likely related to overwhelmed perivascular clearance.
Vascular Exclusion Criteria for Anti-Amyloid Therapy
- History of stroke or TIA within the past 12 months
- >4 cerebral microbleeds or any macrohemorrhage >10 mm in diameter on SWI/T2*
- Cortical superficial siderosis
- Significant FLAIR white matter hyperintensities
- Multiple lacunar strokes or any major vascular territory stroke
- MRI findings consistent with CAA or CAA-related inflammation (patients at significantly increased risk for ARIA)
- These criteria underscore the importance of thorough vascular imaging assessment before initiating anti-amyloid therapy in any patient with cognitive impairment
Health Disparities in VCI Prevention
Black and Hispanic or Latino adults are disproportionately affected by AD and related dementias, with 1.5 to 2 times the risk compared with non-Hispanic White adults. Much of this disparity is attributable to a higher prevalence of cardiovascular risk factors — including hypertension, diabetes, and smoking — in historically marginalized populations. Older Black adults have greater MRI white matter hyperintensity burden and greater mixed brain pathologies at autopsy. Social determinants of health are now recognized by the AHA as a fundamental component of cardiovascular health. Addressing health care inequities — including limited access to preventive care, lower educational attainment, implicit bias in disease management, and lack of social support — is essential for realizing equitable VCI prevention outcomes.
References
- Silbert LC. Vascular cognitive impairment. Continuum (Minneap Minn). 2024;30(6, Dementia):1699-1725.
- Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347-1351.
- PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J. 2003;24(5):475-484.
- SPRINT MIND Investigators. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561.
- Dolui S, Detre JA, Gaussoin SA, et al. Association of intensive vs standard blood pressure control with cerebral blood flow. JAMA Neurol. 2022;79(4):380-389.
- Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). Lancet. 2015;385(9984):2255-2263.
- Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA). Lancet. 2016;388(10046):797-805.
- Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT). Lancet Neurol. 2017;16(5):377-389.
- Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia. Stroke. 2003;34(10):2323-2330.
- Mobius HJ, Stoffler A. Memantine in vascular dementia. Int Psychogeriatr. 2003;15(Suppl 1):207-213.
- Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health. Circulation. 2022;146(5):e18-e43.
- Gorelick PB, Furie KL, Iadecola C, et al. Defining optimal brain health in adults: a presidential advisory from the AHA/ASA. Stroke. 2017;48(10):e284-e303.
- Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and TIA. Stroke. 2021;52(7):e364-e467.
- Meschia JF, Worrall BB, Elahi FM, et al. Management of inherited CNS small vessel diseases: the CADASIL example. Stroke. 2023;54(10):e452-e464.
- Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC scientific expert panel. J Am Coll Cardiol. 2019;73(25):3326-3344.
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377.
- Alzheimer’s Association. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19(4):1598-1695.